



#5 11/92
Power of Attorney

Appl. No. To be assigned
(U.S. Nat'l Phase of PCT/EP99/00524)
Docket Number: 0652.2100000
BI Ref. No. 0652.2100000

RECEIVED

POWER OF ATTORNEY FROM ASSIGNEE

OCT 06 2000

TECH CENTER 1800/2000

Boehringer Ingelheim International GmbH, a corporation of Germany, having a principal place of business at Binger Straße 173, D-55216 Ingelheim am Rhein, Germany, is assignee of the entire right, title and interest for the United States of America (as defined in 35 U.S.C. § 100), by reason of an Assignment to the Assignee executed on July 25, 2000; July 28, 2000; July 25, 2000; of an invention known as Vaccine Formulations (Attorney Docket No. 0652.2100000), which is disclosed and claimed in a patent application of the same title by the inventors Michael Buschle, Max Birstiel and Walter Schmidt (said application filed on to be filed at the U.S. Patent and Trademark Office, having Application Number to be assigned, which is the U.S. National Phase of PCT/EP99/00524, international filing date: 27 January 1999).

REF
Reg No
34,331
Aug 9, 2000


The Assignee hereby appoints the following U.S. attorneys to prosecute this application and any continuation, divisional, continuation-in-part, or reissue application thereof, and to transact all business in the U.S. Patent and Trademark Office connected therewith: Robert Greene Sterne, Esq., Reg. No. 28,912; Edward J. Kessler, Esq., Reg. No. 25,688; Jorge A. Goldstein, Esq., Reg. No. 29,021; Samuel L. Fox, Esq., Reg. No. 30,353; David K.S. Cornwell, Esq., Reg. No. 31,944; Robert W. Esmond, Esq., Reg. No. 32,893; Tracy-Gene G. Durkin, Esq., Reg. No. 32,831; Michele A. Cimbala, Esq., Reg. No. 33,851; Michael B. Ray, Esq., Reg. No. 33,997; Robert E. Sokohl, Esq., Reg. No. 36,013; Eric K. Steffe, Esq., Reg. No. 36,688; Michael Q. Lee, Esq., Reg. No. 35,239; Steven R. Ludwig, Esq., Reg. No. 36,203; Raz E. Fleshner, Esq., Reg. No. 34,331; John M. Covert, Esq., Reg. No. 38,759; and Linda E. Alcorn, Esq., Reg. No. 39,588. The Assignee hereby grants said attorneys the power to insert on this Power of Attorney any further identification that may be necessary or desirable in order to comply with the rules of the U.S. Patent and Trademark Office.

Send correspondence to:

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.
1100 New York Avenue, N.W.
Suite 600
Washington, D.C. 20005-3934
U.S.A.

Direct phone calls to 202-371-2600.

FOR: Boehringer Ingelheim International GmbH
SIGNATURE: [Signature]
BY: Dr. Dieter Laudien
TITLE: Corporate Patent Director
DATE: Aug. 2, 2000



Appl. N. To be assigned
U.S. Nat'l Phase of PCT/EP99/00524)
Docket Number: 0652.2100000
BI Ref. No.: 14/043-US

Certificate Under 37 C.F.R. § 3.73(b)

Applicant: Buschle et al.

Application No.: To be assigned, which is the U.S. National Phase of PCT/EP99/00524 Filed: to be filed,
international filing date: 27 January 1999

Entitled: Vaccine Formulations

Boehringer Ingelheim International GmbH, a corporation
(Name of Assignee) (Type of Assignee, e.g., corporation, partnership, university, government agency, etc.)

states that it is:

1. ☒ the assignee of the entire right, title, and interest, or
2. ☐ an assignee of an undivided part interest

in the patent application/patent identified above by virtue of either:

- A. ☒ An Assignment from the inventors of the patent application identified above. The assignment was recorded in the Patent and Trademark Office at Reel to be recorded, Frame to be recorded, or for which a copy thereof is attached.

OR

- B. ☐ A chain of title from the inventor(s) of the patent application/patent identified above to the current assignee as shown below:

1. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
2. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.
3. From: _____ To: _____
The document was recorded in the Patent and Trademark Office at
Reel _____, Frame _____, or for which a copy thereof is attached.

☐ Additional documents in the chain of title are listed on a supplemental sheet.

☒ Copies of assignments or other documents in the chain of title are attached.

[NOTE: A separate copy (i.e., the original assignment document or a true copy of the original document) must be submitted to Assignment Division in accordance with 37 CFR Part 3, if the assignment is to be recorded in the records of the PTO. See MPEP 302-302.8]

The undersigned (whose title is supplied below) is empowered to act on behalf of the assignee.

Date: ☒ Aug. 2, 2000

Name: Dr. Dieter Laudien

Title: Corporate Patent Director

Signature: ☒ [Signature]
P:\USERS\VP\Choi\0652\210\0652-210.ccr
SKGT Rev. 3/1 1/00 mdc

BEST AVAILABLE COPY

DUPLICATE

Appl. No. To be assigned
(U.S. Nat'l Phase of PCT/EP99/00524)
Docket Number: 0652.2100000
BI Ref. No.: 14/043-US

ASSIGNMENT

In consideration of the sum of One Dollar (\$1.00) or equivalent and other good and valuable consideration paid to each of the undersigned inventors: Michael Buschle, Max Birnstiel and Walter Schmidt, the undersigned inventors hereby sell and assign to Boehringer Ingelheim International GmbH (the Assignee) their entire right, title and interest, including the right to sue for past infringement and to collect for all past, present and future damages:

check applicable box(es) ☒ for the United States of America (as defined in 35 U.S.C. § 100),
☒ and throughout the world,

(a) in the invention(s) known as Vaccine Formulations for which application(s) for patent in the United States of America has (have) been executed by the undersigned on July 25, 2000; July 25, 2000; July 25, 2000, respectively (also known as United States Application No. to be assigned, filed to be filed, which is the U.S. National Phase of PCT/EP99/00524; international filing date: 27 January 1999 in any and all applications thereon, in any and all Letters Patent(s) therefor, and

(b) in any and all applications that claim the benefit of the patent application listed above in part (a), including continuing applications, reissues, extensions, renewals and reexaminations of the patent application or Letters Patent therefor listed above in part (a), to the full extent of the term or terms for which Letters Patents issue, and

(c) in any and all inventions described in the patent application listed above in part (a), and in any and all forms of intellectual and industrial property protection derivable from such patent application, and that are derivable from any and all continuing applications, reissues, extensions, renewals and reexaminations of such patent application, including, without limitation, patents, applications, utility models, inventor's certificates, and designs together with the right to file applications therefor; and including the right to claim the same priority rights from any previously filed applications under the International Agreement for the Protection of Industrial Property, or any other international agreement, or the domestic laws of the country in which any such application is filed, as may be applicable;

all such rights, title and interest to be held and enjoyed by the above-named Assignee, its successors, legal representatives and assigns to the same extent as all such rights, title and interest would have been held and enjoyed by the Assignor had this assignment and sale not been made.

The undersigned inventors agree to execute all papers necessary in connection with the application(s) and any continuing (continuation, divisional, or continuation-in-part), reissue, reexamination or corresponding application(s) thereof and also to execute separate assignments in connection with such application(s) as the Assignee may deem necessary or expedient.

The undersigned inventors agree to execute all papers necessary in connection with any interference or patent enforcement action (judicial or otherwise) related to the application(s) or any continuing (continuation, divisional, or continuation-in-part), reissue or reexamination application(s) thereof and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such interference or patent enforcement action.

The undersigned inventors hereby represent that they have full right to convey the entire interest herein assigned, and that they have not executed, and will not execute, any agreement in conflict therewith.

BEST AVAILABLE COPY

Appl. No. To be assigned
(U.S. Nat'l Phase of PCT/EP99/00524)
Docket Number: 0652.2100000
BI Ref. No.: 14/043-US

The undersigned inventors hereby grant Robert Greene Sterne, Esquire, Registration No. 28,912; Edward J. Kessler, Esquire, Registration No. 25,688; Jorge A. Goldstein, Esquire, Registration No. 29,021; Samuel L. Fox, Esquire, Registration No. 30,353; David K.S. Cornwell, Esquire, Registration No. 31,944; Robert W. Esmond, Esquire, Registration No. 32,893; Tracy-Gene G. Durkin, Esquire, Registration No. 32,831; Michele A. Cimbala, Esquire, Registration No. 33,851; Michael B. Ray, Esquire, Registration No. 33,997; Robert E. Sokohl, Esquire, Registration No. 36,013; Eric K. Steffe, Esquire, Registration No. 36,688; Michael Q. Lee, Esquire, Registration No. 35,239; Steven R. Ludwig, Esquire, Registration No. 36,203; Raz E. Fleshner, Esquire, Registration No. 34,331; John M. Covert, Esquire, Registration No. 38,759; and Linda E. Alcorn, Esquire, Registration No. 39,588; all of STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C., 1100 New York Avenue, N.W., Suite 600, Washington, D.C. 20005-3934, power to insert in this assignment any further identification that may be necessary or desirable in order to comply with the rules of the United States Patent and Trademark Office for recordation of this document.

IN WITNESS WHEREOF, executed by the undersigned inventors on the date opposite their names.

Date: 07/25/2000

Signature of Inventor: 

Michael Buschle

Date: 07/26/2000

Signature of Inventor: 

Max Birnstiel

Date: 7/25/2000

Signature of Inventor: 

Walter Schmidt

P:\USERS\PChef\0652\210\0652-210.aag